EP. 1: Importance of Biomarker Testing for Solid Tumors
Benjamin Levy, MD, and a multispecialty panel of experts discuss the importance of biomarker-directed therapy for appropriate solid tumors.
EP. 3: Pan-Tumor Biomarker Testing in Oncology
A panel of oncology experts in lung, thyroid, and sarcomatous tumors discuss the role and impact of pan-tumor biomarker testing.
EP. 5: Solid Tumors: Unmet Needs Related to Biomarker-Driven Therapy
Dr Mark Socinski and panel discuss the challenges and unmet meets of biomarker-driven therapy across solid tumor types.
EP. 8: TRK Fusion Inhibitors in Tumor-Agnostic Clinical Trials
Jonathan Trent, MD, PhD, describes the safety and efficacy data from clinical trials of larotrectinib in patients with NRTK fusion–positive solid tumors.